AVDLAVADEL PHARMACEUTICALS PLC

Nasdaq avadel.com


$ 14.25 $ -0.25 (-1.73 %)    

Monday, 09-Sep-2024 15:59:59 EDT
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 14.24
$ 14.28
$ 14.25 x 100
$ 14.26 x 575
$ 14.06 - $ 14.48
$ 13.42 - $ 19.09
992,079
na
1.37B
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-29-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-09-2023 06-30-2023 10-Q
6 05-04-2023 03-31-2023 10-Q
7 03-29-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-16-2022 12-31-2021 10-K
12 11-08-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-10-2021 03-31-2021 10-Q
15 03-09-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-15-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-09-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-28-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
33 08-15-2016 06-30-2016 10-Q
34 05-10-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 avadel-pharmaceuticals-announces-publication-of-restore-data-highlighting-challenges-with-twice-nightly-oxybates-and-strong-patient-preference-for-once-nightly-lumryz-dosing-extended-release-oral-suspension

– Survey data demonstrate 94% of people with narcolepsy prefer the once-nightly regimen of LUMRYZ over twice-nightly oxybate re...

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 hc-wainwright--co-reiterates-buy-on-avadel-pharmaceuticals-maintains-27-price-target

HC Wainwright & Co. analyst Oren Livnat reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $27 pri...

 avadel-pharmaceuticals-announces-publication-in-clinical-therapeutics-of-data-highlighting-weight-loss-in-people-with-narcolepsy-treated-with-lumryz-extended-release-oral-suspension

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, tod...

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 avadel-pharmaceuticals-q2-2024-adj-eps-014-beats-016-estimate-sales-4150m-beat-3753m-estimate

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...

 avadel-pharmaceuticals-announces-first-patient-dosed-in-phase-3-revitalyz-trial-of-lumryz-extended-release-oral-suspension-for-the-treatment-of-idiopathic-hypersomnia

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, ann...

 avadel-pharmaceuticals-to-join-russell-3000-index-effective-at-the-open-of-us-equity-markets-on-monday-july-1-2024

Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, ann...

 avadel-pharmaceuticals-shares-new-lumryz-for-extended-release-oral-suspension-data-at-sleep-2024-june-1-5-2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentatio...

 hc-wainwright--co-maintains-buy-on-avadel-pharmaceuticals-raises-price-target-to-27

HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price t...

 craig-hallum-maintains-buy-on-avadel-pharmaceuticals-raises-price-target-to-23

Craig-Hallum analyst Chase Knickerbocker maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price targ...

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 avadel-pharmaceuticals-q1-cash-and-equivalents-888m

Cash, cash equivalents and marketable securities were $88.8 million as of March 31, 2024.

 avadel-pharmaceuticals-q1-2024-gaap-eps-030-misses-021-estimate-revenue-0

Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate...

 needham-reiterates-buy-on-avadel-pharmaceuticals-maintains-22-price-target

Needham analyst Ami Fadia reiterates Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and maintains $22 price target.

 american-airlines-to-rally-around-42-here-are-10-top-analyst-forecasts-for-tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 craig-hallum-maintains-buy-on-avadel-pharmaceuticals-raises-price-target-to-22

Craig-Hallum analyst Chase Knickerbocker maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price targ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION